1. Introduction {#sec1}
===============

Management of complicated intra-abdominal infections (cIAIs) in Asia remains challenging, and differs in important aspects from practices in the West. Disease patterns differ, and available resources including operating facilities, ancillary personnel and imaging equipment vary from one region to another. Importantly, microbial resistance and access to specific antimicrobial agents varies from region to region.

Available guidelines on the management of cIAIs are predominantly written for the Western context [@bib1; @bib2], although Asian guidance on antimicrobial therapy for cIAIs has been previously developed [@bib3]. The current document outlines the microbiological profiles of IAIs in the Asian region for comparison with the West, and explores antimicrobial resistance in key pathogens causing IAIs in Asia. We also provide updated guidance on antimicrobial management of cIAIs in the Asian setting.

2. Methods {#sec2}
==========

The Asian Consensus Taskforce on Complicated Intra-Abdominal Infections (ACT-cIAI) met and discussed current clinical approaches to cIAI management in Asia, international guidelines on cIAI management, microbiological trends of cIAI pathogens in Asia, and the existing antibiotic options. A steering committee was formed to explore differences between Asia and the West. Where applicable, existing guidelines were consulted, including the American Infectious Diseases Society of America (IDSA)/Surgical Infection Society (SIS) guidelines, as well as published recommendations from the Asian region. Microbiology data on cIAI pathogens and data on bacterial resistance rates in Asian countries were obtained from published surveillance studies and the Tigecycline Evaluation and Surveillance Trial (TEST) database.

After a second meeting to review and refine the compiled document, the revised document was circulated to the Taskforce for final review and comments. The final document is endorsed by the International Surgical Infections Study (ISIS) Group.

3. Definitions {#sec3}
==============

In accordance with the American IDSA/SIS guidelines, we are defining cIAIs as an infection that "extends beyond the hollow viscus of origin into the peritoneal space and is associated with either abscess formation or peritonitis" [@bib1].

4. Clinical epidemiology of cIAIs in Asia {#sec4}
=========================================

4.1. Key pathogens causing cIAIs in Asia {#sec4.1}
----------------------------------------

Chief amongst factors influencing the success of management of cIAI in Asia is the high prevalence of antimicrobial resistance, especially amongst Enterobacteriaceae. Data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) [@bib4] provide the best available evidence for the current status of cIAI infections in Asia, but limitations include the small number of contributing sites per country and the selection process for test organisms. These sites are usually major teaching or tertiary-care centers, which potentially creates sample bias. Another limitation is that in vitro susceptibility results do not necessarily predict clinical success or failure. Furthermore, although isolates are divided into those obtained from cultures collected \<48 h and ≥48 h after hospital admission to differentiate community-acquired from nosocomial infections, the time of collection may not represent the true time of acquisition of infection [@bib5]. Thus, the SMART results may not accurately reflect the patterns of pathogen distribution in community versus healthcare settings. However, the results are useful in comparing gross trends between Asia and other global regions.

Reports from Asia--Pacific countries participating in SMART confirm the polymicrobial basis for cIAI. Enterobacteriaceae were the most frequently isolated microorganisms in patients with cIAIs, comprising 68.3%--89.5% [@bib6; @bib7; @bib8]. Of these, *Escherichia coli* and *Klebsiella pneumoniae* were the most common, like the West, with *Enterobacter* spp, including *Enterobacter cloacae*, found at lower rates. Whilst *Pseudomonas aeruginosa* featured across the world as a non-Enterobacteriaceae pathogen, *Acinetobacter baumannii* was more prominent in the Asian setting. In some areas, including Asia, *Aeromonas hydrophila* and *Citrobacter freundii* have also been implicated in these polymicrobial infections [@bib9]. However, the pattern of bacterial causes of cIAI infections varies across the Asia--Pacific region. [Table 1](#tbl1){ref-type="table"} shows the most common pathogens causing IAIs in selected Asian countries, alongside data from the USA and Europe [@bib7; @bib9; @bib10; @bib11; @bib12; @bib13; @bib14; @bib15; @bib16; @bib17; @bib18].

4.2. Antimicrobial resistance in pathogens causing cIAIs in Asia {#sec4.2}
----------------------------------------------------------------

Isolates from Asia--Pacific countries showed the highest levels of antimicrobial resistance of the global regions included the SMART study, and a trend of increasing resistance continues year by year [@bib5; @bib10]. Within the region, resistance rates can vary between countries; for example, resistance in Enterobacteriaceae in China and India was higher than in the other countries of this region, especially to ampicillin--sulbactam, fluoroquinolones, and cephalosporins [@bib8]. Updated results from ongoing monitoring continue to confirm high levels of resistance [@bib8; @bib18]. The high resistance rate of Enterobacteriaceae isolates to ampicillin--sulbactam supports the guideline recommendation against using ampicillin--sulbactam for patients with IAIs, especially in severe cases [@bib1; @bib3].

Production of β-lactamases is among the most common and clinically significant of the resistance mechanisms for Gram-negative bacilli [@bib19]. Multiple types of β-lactamases exist ([Table 2](#tbl2){ref-type="table"}) [@bib19; @bib20], and bacteria usually carry several simultaneously. Clinically, the extended-spectrum β-lactamases (ESBLs) are a particular concern. [@bib20]

4.3. ESBLs in Asia and ESBL-producing pathogens causing IAIs {#sec4.3}
------------------------------------------------------------

ESBLs almost certainly emerged *de novo* in Asia, with early resistance studies detecting elevated levels of ESBL phenotypes, particularly among *Klebsiella* isolates and particularly in China, South Korea, Japan and India [@bib21].

Data from the SMART study for 2005--2010 show that the Asia--Pacific region has consistently had the highest ESBL positivity rates for *E. coli*, *K. pneumoniae* and *Klebsiella oxytoca* isolated from IAIs ([Fig. 1](#fig1){ref-type="fig"}) [@bib22]. As of 2012, ESBL production amongst targeted Enterobacteriaceae isolates in the Asia--Pacific region was higher than other geographic areas, at nearly 40% [@bib23]. Amongst isolates from ICU patients in Vietnam and the Philippines, the prevalence of ESBL-producers was as high as 81.0% and 58.8%, respectively [@bib23]. However, this trend is not uniform across Asia. In Taiwan, the rates of ESBL-producing *E. coli* and *K. pneumoniae* were 7.5% and 7.0%, respectively, among 610 Enterobacteriaceae isolates [@bib8]. ESBL positivity rates were lower among isolates recovered from patients with community-acquired IAIs than those with hospital-acquired infections (3.6% vs. 13.9% for *E. coli* and 2.4% vs. 13.3% for *K. pneumoniae* isolates, respectively) [@bib8]. [Fig. 2](#fig2){ref-type="fig"} illustrates the marked variability across the Asia--Pacific region in the prevalence of ESBL-producing *E. coli* and *K. pneumoniae* isolates from IAIs [@bib18].

Although not as prevalent as enterobacteria, multidrug-resistant *A. baumannii* and *P. aeruginosa* are also implicated in cIAIs, particularly post-operative infections. Their rates of resistance are far higher: 29.8% of *P. aeruginosa* and 73.0% of *A. baumannii* isolates were not susceptible to at least one carbapenem in 2010 data from the Comparative Activity of Carbapenem Testing (COMPACT) II study [@bib23]. A separate study of *P. aeruginosa* isolates from ICU patients in 19 Chinese hospitals reported a marked decrease in susceptibility to imipenem (from 81% to 62%) between 1996 and 2002 [@bib24].

The advent of New Delhi metallo-β-lactamase-1 (NDM-1) *K. pneumoniae* heralded the emergence of carbapenamases amongst Enterobacteriaceae in Asia. Medical tourism within the region has compounded the problem, facilitating geographical spread of NDM-1 *Klebsiella* spp [@bib25].

5. Recommended antimicrobial regimens {#sec5}
=====================================

Whilst antibiotics have an important role, source control must be addressed in all cases of cIAIs to avoid prolonging morbidity and begetting resistance.

Initiation of antimicrobial therapy should occur as soon as an IAI is diagnosed or considered likely [@bib1] (i.e., within 4--6 h). For patients with septic shock, antibiotics should be administered as soon as possible [@bib1] (i.e., within 1 h).

Appropriate choices of antibiotics for cIAIs are best guided by local antibiograms and resistance patterns. However, if such information is not readily available, general principles governing the judicious use of antibiotics should be applied.

Firstly, patients at risk for ESBL acquisition or multidrug-resistant *P. aeruginosa* or *A. baumannii* should be identified. The prevalence of ESBL-producing organisms implicated in cIAIs in Asia makes it imperative that moderate to severely ill patients with cIAIs with such risks are treated correctly at the outset to mitigate morbidity and mortality. Secondly, broad-spectrum antibiotic use should be avoided when the risk of infection with ESBL-producing pathogens is low or absent; for example, in community-acquired infections particularly where the community prevalence of ESBL organisms is \<20%. Furthermore, a recent Indian study concluded that broad-spectrum agents are not required for mild infections even in areas with high prevailing ESBL rates [@bib26]. Finally, antibiotic stewardship should be adopted across Asia as a pivotal strategy to stem the tide of 'delinquent' antibiotic use in hospitals and in the community.

Antibiotic recommendations are based on community versus hospital acquisition and clinical severity of illness, which define relative risks for acquiring resistant flora. [Table 3](#tbl3){ref-type="table"} outlines suggested antimicrobial regimens for treating IAIs in the Asian region. This information is based on our review of the existing data and the consensus of this group, the ACT-cIAI.

Cost is an important factor in Asia, and must be taken into consideration in any discussion of medical practice patterns. The direct cost of the medication can influence choice of therapy, particularly if patients must pay for medicines as an out-of-pocket expense. In addition, inappropriate initial antibiotic use (i.e., use of an agent the causative pathogen is not susceptible to) has cost implications; it has been shown to significantly raise patient care costs [@bib27].

6. Tropical infections {#sec6}
======================

A unique aspect of management in Asia is the existence of several tropical infections that can produce cIAI. These infections are more common in rural than urban centers.

Clinicians should be aware of the differential diagnosis of intra-abdominal sepsis, including tropical infectious disease conditions such as abdominal tuberculosis, salmonellosis, ascariasis, and amebiasis. Dengue hemorrhagic fever and malaria may also present symptoms overlapping with cIAI. [Table 4](#tbl4){ref-type="table"} presents several tropical conditions, their symptoms and typical treatment.

7. Management illustration: antibiotic therapy in acute cholangitis {#sec7}
===================================================================

The presentation of acute cholangitis varies from mild biliary colic to septic shock. Patients with acute cholangitis may deteriorate rapidly and progress to a life-threatening critical condition [@bib29], underscoring the importance of early diagnosis.

The five orders of clinical management for acute cholangitis are hemodynamic stabilization, assessment, intensive care, antimicrobial therapy, and biliary decompression with definitive therapy. Clinical judgment in the sequencing and timing of these therapeutic activities has a significant impact on clinical outcome.

7.1. Microbiology {#sec7.1}
-----------------

The most frequent pathogens are the gastrointestinal flora *E. coli,* and *Klebsiella, Enterobacter* and *Enterococcus* spp ([Table 5](#tbl5){ref-type="table"}) [@bib30; @bib31; @bib32]. *Streptococcus* and *Proteus* spp are less frequently involved [@bib33]. Anaerobes, such as *Clostridium* and *Bacteroides* spp, have been isolated in 4%--20% of bile cultures from patients with acute biliary infections [@bib34]. Empirical coverage for these organisms is advised in cases of bilioenteric anastamoses. Resistant pathogens may be encountered in patients with healthcare-associated infections and empirical coverage should be adjusted accordingly. Once bacteriology and susceptibility data are available, the most appropriate antibiotics must be selected.

7.2. Antimicrobial therapy {#sec7.2}
--------------------------

Antimicrobial therapy should be initiated as soon as the diagnosis of biliary infection is suspected and should definitely commence before any procedure is performed [@bib34]. For patients in septic shock, antimicrobials should be administered within 1 h of recognition; for others, up to 4 h may elapse before beginning antimicrobial therapy [@bib34].

In general, the principles and concepts of antimicrobial choice are based on knowledge of the most likely offending microorganism, the pharmacokinetics, pharmacodynamics and potential adverse effects of the drugs, local antimicrobial susceptibility data, the severity of infection, history of antimicrobial medications, and the patient\'s pathophysiological and immunological status. The availability and cost of the drugs may be factors for consideration. The selection of this empiric regimen is outlined in [Table 3](#tbl3){ref-type="table"}, and varies based on the resistance profile of organisms, particularly *E. coli*. When culture and susceptibility data become available, therapy is revised to a more targeted narrow-spectrum therapy. Patients who are unresponsive to antibiotic therapy may require urgent or early biliary drainage or cholecystectomy.

The recommended antimicrobial therapy protocol will differ between institutions because of differences in the local susceptibility of the microorganisms and drug availability. An antibiotic stewardship program will provide a relevant guide to the choice of antimicrobial therapy.

In the management of acute cholangitis, the choice of antimicrobial agents is guided by the severity of infection. This practice is consistent with the IDSA guidelines for IAIs [@bib1]. For grade I acute cholangitis, the recommended antimicrobials in the Tokyo Guidelines 2013 are first- or second-generation cephalosporins (e.g., cefazolin, cefuroxime), ertapenem or fluroquinolones [@bib34]. Coverage of anaerobic bacteria is generally not indicated unless an endobiliary stent or a biliary-enteric anastomosis is present, or for immunocompromised patients. Consistent with the North American guidelines, ampicillin/sulbactam is not recommended unless an aminoglycoside is added, because of limited antimicrobial activity against *E. coli* [@bib1].

Antimicrobial recommendations for grade II and III (see [Table 6](#tbl6){ref-type="table"}) [@bib35] acute cholangitis include wide-spectrum penicillin/tazobactam, third- or fourth-generation cephalosporins, fluoroquinolones or carbapenems (imipenem/cilastin, meropenem, doripenem), or aztreonam [@bib34]. Additional coverage for anaerobes with metronidazole 500 mg IV given every 6--8 h is indicated for patients with bilio-enteric anastomosis or biliary stents [@bib36]. For patients with suspected hospital-acquired multidrug-resistant organisms -- especially patients with indwelling stents and malignancies -- antibiotics should be selected accordingly. Vancomycin is recommended for grade III community-acquired acute cholangitis to cover *Enterococcus* spp and it may be added for hospital-acquired MRSA biliary infections of any severity. In the presence of vancomycin-resistant *Enterococcus* (VRE), linezolid, daptomycin or tigecycline are recommended.

To achieve the best clinical outcome, the drug dosage must be titrated according to the patient\'s renal and hepatic function, particularly for patients with septicemic shock. The recommended duration of antimicrobial treatment for grades II and III acute cholangitis ranges from 4 to 7 days. Antimicrobial therapy should not be discontinued before the clearance of obstruction or calculi in the biliary tract. To mitigate the risk of infective endocarditis, at least 2 weeks of antimicrobial therapy is recommended if Gram-positive cocci, such as *Enterococcus* spp and *Streptococcus* spp, are diagnosed [@bib34].

7.3. Antibiotic stewardship -- an essential practice {#sec7.3}
----------------------------------------------------

The prolonged, improper, and unregulated use of antibiotics is a key factor in the rapid rise of resistant pathogens in Asia over the past decade. Therefore, implementing antibiotic stewardship measures in Asian hospitals is particularly important to reduce selection pressure on resistant pathogens and slow their rise. Proper antibiotic use is also an important part of providing quality clinical care.

The essential components of antibiotic stewardship programs are provided in existing guidelines [@bib37; @bib38]. Several strategies are effective in the institutional setting: developing a multidisciplinary team, close collaboration with the infection control program, prospective audit and feedback to the prescriber, and computer-assisted audit and surveillance [@bib38].

Educational programs on topics such as appropriate drug selection, dosing, route, and duration of antimicrobial therapy will facilitate good stewardship. Implementation of these strategies, along with regular surveys of the diversity and quantity of antimicrobials used and any changes in resistance patterns, are crucial to the success of institutional stewardship programs.

8. Conclusion {#sec8}
=============

Selection of appropriate empiric antibiotic therapy is critical for preventing unnecessary morbidity and mortality from cIAIs. Consideration of regional epidemiological data and regional resistance profiles is essential for antibiotic selection [@bib3]. The aim of this paper was to provide updated recommendations on antibiotic therapy for IAIs based on the latest microbiological and resistance data available for Asia. We have examined SMART data and presented an overview of the local microbiological profiles for cIAIs as well as the antibiotic resistance patterns for key pathogens. From this, we have proposed antimicrobial therapies suitable for treating cIAIs in patients in Asian settings, which we hope will prove beneficial to local physicians managing IAIs.

Considerable gaps remain in our knowledge of the epidemiology and antimicrobial resistance among pathogens causing IAIs in many Asian countries. Addressing this issue will help physicians confidently select antibiotic therapies for cIAIs that are appropriate and specific to their location.
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![Prevalence of ESBL producers among *E. coli* and *K. pneumoniae* isolates from IAIs in 11 Asia--Pacific countries in 2010 [@bib18]. Reprinted from *Int J Antimicrob Agents*, Volume 40 Supplement, Huang CC, et al., Impact of revised CLSI breakpoints for susceptibility to third-generation cephalosporins and carbapenems among Enterobacteriaceae isolates in the Asia--Pacific region: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2002--2010, S4--S10, 2012, with permission from Elsevier.](gr2){#fig2}

###### 

Top five pathogens causing IAIs in selected Asian and Western countries.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Country                                                   Rank                                                                                                                       
  --------------------------------------------------------- -------------------------------- ------------------------------- ---------------------------- ---------------------------- --------------------------
  Asia--Pacific [@bib10]\                                   *E. coli* (48.5%)\               *K. pneumoniae* (20.2%)\        *P. aeruginosa* (10.5%)      *A. baumannii* (5.0%)        *E. cloacae* (4.6%)
  (*N* = 2189 isolates)                                     (ESBL+ = 19.8%; ESBL− = 28.7%)   (ESBL+ = 4.3%; ESBL− = 15.9%)                                                             

  China [@bib7]\                                            *E. coli* (49.2%)\               *K. pneumoniae* (16.9%)\        *P. aeruginosa* (8.4%)       *E. cloacae* (5.8%)          *A. baumannii* (4.6%)
  (*N* = 3420 isolates)                                     (ESBL+ = 25.8%; ESBL− = 23.4%)   (ESBL+ = 5.6%; ESBL− = 11.3%)                                                             

  Indonesia[a](#tbl1fna){ref-type="table-fn"}               *E. coli* (20.4%)                *K. pneumoniae* (13.3%)         *S. aureus* (10.9%)          *P. aeruginosa* (8.4%)       *S. haemolyticus* (7.1%)

  Singapore [@bib11; @bib12]                                *E. coli* (20--25%)              *K. pneumoniae*                 *Pseudomonas* spp            *Bacteroides* spp            *Enterococcus* spp

  Thailand [@bib13]\                                        *E. coli* (36%)                  *K. pneumoniae* (12%)           *P. aeruginosa* (8%)         *A. baumannii* (4%)          *Enterococcus* spp (3%)
  (*N* = 1305 isolates)                                                                                                                                                                

  Taiwan [@bib14]\                                          *E. coli* (38.8%)                *K. pneumoniae* (23.5%)         *P. aeruginosa* (9.3%)       *E. cloacae* (6.1%)          *A. baumannii* (3.8%)
  (*N* = 2417 isolates)                                                                                                                                                                

  India [@bib15]\                                           *E. coli* (62.7%)                *K. pneumoniae* (16.6%)         *P. aeruginosa* (5.4%)       *C. freundii* (2.2%)         *A. baumannii* (2.0%)
  (*N* = 542 isolates)                                                                                                                                                                 

  Philippines [@bib16][b](#tbl1fnb){ref-type="table-fn"}\   *E. coli* (35%)                  *K. pneumoniae* (15%)           *P. aeruginosa* (14%)        *E. cloacae* (6%)            *A. baumannii* (5%)
  (*N* = 77 patients)                                                                                                                                                                  

  Korea [@bib17][b](#tbl1fnb){ref-type="table-fn"}\         *E. coli* (22.1%)                *P. aeruginosa* (15.7%)         *Enterococcus* spp (15.2%)   *Enterobacter* spp (12.5%)   *K. pneumoniae* (11.4%)
  (*N* = 256 isolates)                                                                                                                                                                 

  USA [@bib9]\                                              *E. coli* (43.4%)\               *K. pneumoniae* (15.1%)\        *P. aeruginosa* (14.3%)      *E. cloacae* (7.4%)          *P. mirabilis* (3.5%)
  (*N* = 1522 isolates)                                     (ESBL+ = 4.8%)                   (ESBL+ = 9.5%)                                                                            

  Europe [@bib9]\                                           *E. coli* (51.6%)\               *K. pneumoniae* (9.7%)\         *P. aeruginosa* (8.0%)       *E. cloacae* (6.2%)          *P. mirabilis* (4.7%)
  (*N* = 7844 isolates)                                     (ESBL+ = 8.0%)                   (ESBL+ = 16.2%)                                                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Single-institution data from appendicitis cases in Dr Hasan Sadikin Hospital, Bandung, Indonesia (Usman N, unpublished data, 2012).

Data from single-center study of bile cultures from cholangitis cases.

###### 

Major groups of β-lactamases in Gram-negative bacteria that threaten the role of β-lactam antibiotics.

  Functional group   Common name                            Examples                         β-Lactams to which resistance is conferred
  ------------------ -------------------------------------- -------------------------------- ------------------------------------------------------------------------------
  1                  Cephalosporinase                       AmpC                             Penicillins, cephalosporins
  2b                 Broad-spectrum penicillinase           TEM-1, SHV-1                     Penicillins, early cephalosporins
  2be                Extended-spectrum β-lactamases         TEM-10, SHV-2, CTX-M-type, VEB   Penicillins, cephalosporins, monobactams, β-lactamase inhibitor combinations
  2d                 Oxacillin hydrolyzing/Cloxacillinase   OXA-1 to 11, PSE-2               Penicillins, including oxacillin and cloxacillin
  2df                Carbapenemase                                                           Carbapenems and other β-lactams
  2f                 Carbapenemase                          KPC-1,2, SME-1                   All current β-lactams
  3                  Metallo-β-lactamases                   IMP-1, VIM-1, NDM-1              All β-lactams except monobactams

Adapted from Refs. [@bib19; @bib20].

###### 

Suggested antibiotic regimens for treating community- and hospital-acquired IAIs in the Asian region.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                             Type of therapy                                                                                                                                                                                                                                                                                                                        
  ------------------------------------------ -------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------
  **Community-acquired cIAI**                                                                                                                                                                                                                                                                                                                                                       

  Mild to moderate                           Amoxicillin/clavulanate                                                                Moxifloxacin[b](#tbl3fnb){ref-type="table-fn"}                                                                                         Cefazolin, cefuroxime, ceftriaxone or cefotaxime + metronidazole                                         Levofloxacin + metronidazole\
                                                                                                                                                                                                                                                                                                                                                                                    Ciprofloxacin + metronidazole[b](#tbl3fnb){ref-type="table-fn"}

  Severe                                     Amoxicillin/clavulanate                                                                Moxifloxacin[b](#tbl3fnb){ref-type="table-fn"}\                                                                                        Cefazolin, cefuroxime, ceftriaxone, ceftazidime, cefepime or cefotaxime + metronidazole                  Levofloxacin + metronidazole\
                                                                                                                                    Ertapenem or tigecycline[c](#tbl3fnc){ref-type="table-fn"}\                                                                                                                                                                                     Ciprofloxacin + metronidazole[b](#tbl3fnb){ref-type="table-fn"}
                                                                                                                                    Meropenem, imipenem[e](#tbl3fne){ref-type="table-fn"}/cilastin, doripenem, piperacillin/tazobactam[d](#tbl3fnd){ref-type="table-fn"}                                                                                                            

  **Healthcare-associated cIAI**                                                                                                                                                                                                                                                                                                                                                    

  Mild to moderate                           Meropenem, imipenem, imipenem/cilastin, doripenem or piperacillin/tazobactam [@bib8]   Tigecycline, moxifloxacin, ertapenem[f](#tbl3fnf){ref-type="table-fn"}                                                                 Cefepime or levofloxacin/ciprofloxacin[g](#tbl3fng){ref-type="table-fn"} + metronidazole                 

  Severe[j](#tbl3fnj){ref-type="table-fn"}   Meropenem, imipenem/cilastin or doripenem                                                                                                                                                                                     Meropenem, imipenem/cilastin or doripenem + vancomycin or linezolid[h](#tbl3fnh){ref-type="table-fn"}\   Tigecycline + levofloxacin or ciprofloxacin[h](#tbl3fnh){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                           Tigecycline + aztreonam/ciprofloxacin/levofloxacin                                                       Carbapenem, tigecycline, polymixin B or colistin ± aminoglycoside[i](#tbl3fni){ref-type="table-fn"}\
                                                                                                                                                                                                                                                                                                                                                                                    Carbapenem + tigecycline, polymixin B or colistin[k](#tbl3fnk){ref-type="table-fn"}
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Alternative therapy includes the following considerations: allergy, pharmacology/pharmacokinetics, compliance, costs, and local resistance profiles.

Use in cases of β-lactam allergy.

Alternative to cephalosporin or quinolone monotherapy, if the prevalence of community-acquired ESBL+ or quinolone-resistant *E. coli* is \>20%.

Reserve these antipseudomonal regimens for use in patients with neutropenia, septic shock or who are critically ill.

Use imipenem with caution where there is a high prevalence of increased imipenem MICs in Enterobacteriaceae.

Risk groups for *P. aeruginosa* include patients with neutropenia, septic shock or an indwelling central venous catheter [@bib28].

If hospital-acquired ESBL prevalence is \>20%, use the carbapenems preferentially over piperacillin/tazobactam, cefepime, ceftazidime or levofloxacin.

Use if both hospital-acquired ESBL and MRSA prevalence rates are \>20%.

Use for suspected pseudomonal or *Acinetobacter* infections with reduced susceptibility (tigecycline only for *Acinetobacter*).

Antifungal therapy may be required in selected circumstances as advised in current IDSA guidelines.

Use if carbapenemases (e.g., NDM and KPC) with extended resistance to currently available antibiotics are suspected; also seek expert advice.

###### 

Tropical infectious diseases producing cIAI.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                       Symptoms                                                                                                          Diagnostic options                                                                                                    Treatment                                                              Comments
  ------------------------------- ----------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  Amebic infection                Fever, pain in right upper abdomen, liver tenderness, tachycardia, hepatomegaly, nausea and vomiting, jaundice    Test for *Entamoeba histolytica* via IHA, ELISA, or PCR test for DNA in urine; abdominal ultrasound or CT             Metronidazole, tinidazole                                              Medical management is sufficient for simple amebiasis; for liver abscesses larger than 5 cm, percutaneous drainage may also be required

  Intestinal ascariasis           Intestinal obstruction, vomiting of passing of worms in stool, symptoms of appendicitis                           X-Ray of abdomen; abdominal ultrasound to confirm; gastrograffin                                                      Albendazole, mebendazole                                               Ascariasis is endemic in Asia Pacific. Drug therapy should be followed by repeat stool examination to confirm eradication, as recurrence is common

  Abdominal tuberculosis          Acute or chronic intestinal obstruction, abdominal distention, perforation, enterocutaneous or perianal fistula   Sputum for AFB smear and culture; AFB smear and culture of abdominal biopsy sample; abdominal ultrasound or CT scan   Isoniazid, rifampin, pyrazinamide, ethambutol; plus coverage for IAI   Treatment will depend on the type of abdominal complication. Resistance to drug treatment is a problem in Asia

  Intra-abdominal salmonellosis   Nausea, vomiting, diarrhea, dyspepsia, bloating; in severe cases, perforation or abscess                          Culture for *Salmonella* of blood, stool, rectal swab or gastric washing samples; ultrasound of abdomen               Antibiotic coverage for high-severity IAI\                             Drug resistance is an increasing problem in Asia\
                                                                                                                                                                                                                                                                          Ceftriaxone, cefotaxime; various second-line regimens                  High mortality
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Common pathogens involved in acute cholangitis.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Community acquired                        Hospital acquired                                                            
  ----------------------------------------- ------------------------------------------ --------------------------------- ---------------------------------------------------------------------
  [Gram negative]{.ul}*Escherichia coli*\   [Gram positive]{.ul}*Streptococcus* spp\   *Clostridium* spp\                MDR ESBL-producing *E. coli* and *Klebsiella* spp in the community\
  *Klebsiella pneumoniae*\                  *Enterococcus faecalis*                    *Bacteroides* spp *Proteus* spp   Methicillin-resistant *Staphylococcus aureus*\
  *Enterobacter* spp\                                                                                                    *Acinetobacter baumannii*
  *Citrobacter* spp\                                                                                                     
  *Pseudomonas* spp\                                                                                                     
  *Salmonella typhi*\                                                                                                    
  *Salmonella paratyphi*                                                                                                 

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MDR, multi-drug resistant; ESBL, extended-spectrum beta-lactamase.

###### 

Definitions of grade III and grade II acute cholangitis from TG 13 [@bib38].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Severe (grade III) acute cholangitis is defined as acute cholangitis that is associated with the onset of dysfunction in at least one of the following organs/systems:1.Cardiovascular system -- hypotension requiring dopamine ≥ 5 μg/kg per min or any dose of norepinephrine2.Central nervous system -- change in mental status or consciousness3.Respiratory system -- PaO~2~/FiO~2~ ratio \< 3004.Renal system -- serum creatinine \> 2 mg/dL5.Liver -- PT-INR \> 1.56.Hematological system -- platelets \< 100,000/mm^3^
    
  Moderate (grade II) acute cholangitis is associated with any two of the following:1.Abnormal white blood cell count (\>12,000/mm^3^ or \<4000/mm^3^)2.High fever (≥39 °C)3.Age (≥75 years old)4.Hyperbilirubinemia (total bilirubin ≥5 mg/dL)5.Hypoalbuminemia (\<STD × 0.7)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
